Nuclear Medicine, IRCCS Humanitas, Milan, Italy.
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S41-51. doi: 10.1007/s00259-011-2019-2.
Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.
生长抑素是一种在神经系统中广泛分布的肽类物质,作为几种器官中的神经递质,具有广泛的主要抑制作用,如抑制生长激素的释放,以及抑制胰腺和胃肠激素的释放。已经克隆了五种生长抑素受体亚型,并证明它们在所有人类肿瘤中都有强烈的表达。特别是,2 型受体被确定为神经内分泌肿瘤细胞表面最常表达的受体,为生长抑素类似物的许多临床应用提供了分子基础。在 20 世纪 80 年代末,体内证明了一些肿瘤表面存在生长抑素受体,这引起了人们对受体成像的兴趣,实际上,与正常组织相比,肿瘤细胞上的肽受体过度表达构成了这些肿瘤的分子成像的基础。本文旨在阐述用于研究生长抑素受体的单光子发射放射性药物的发展及其在诊断成像中的应用。